CLYM
Climb Bio, Inc.- Healthcare
- Biotechnology
- $585M market cap
Forecast run · Oct 29, 2026Upside rank 167 of 3,186
Model Signal
ForecastQ Daily Probabilities
58.1%
44.7%
46.2%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$10.19
Price target$28.00
Implied move+174.8%
Analysts7
ForecastQ Portfolios
Company Profile
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.